Breaking News Instant updates and real-time market news.

MRTN

Marten Transport

$21.52

0.31 (1.46%)

, ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

18:49
10/17/19
10/17
18:49
10/17/19
18:49

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Marten Transport (MRTN) up 3.2%... Intuitive Surgical (ISRG) up 3.1%... E-Trade (ETFC) up 3.1%... Western Alliance (WAL) up 1.0%... Atlassian (TEAM) up 0.5%. ALSO HIGHER: Paratek (PRTK) up 5.5%. DOWN AFTER EARNINGS: Gildan (GIL) down 12.4% after negative Q3 pre-announcement... Brandywine Realty (BDN) down 10.9%... Exponent (EXPO) down 6.1%... WD-40 (WDFC) down 5.3%... Vicor Corp (VICR) down 3.6%... Bank OZK (OZK) down 2.0%. Movers as of 18:30ET.

MRTN

Marten Transport

$21.52

0.31 (1.46%)

ISRG

Intuitive Surgical

$529.22

-1.25 (-0.24%)

ETFC

E-Trade

$39.04

0.02 (0.05%)

WAL

Western Alliance

$46.24

0.53 (1.16%)

TEAM

Atlassian

$122.43

-1.91 (-1.54%)

PRTK

Paratek Pharmaceuticals

$3.46

0.05 (1.47%)

GIL

Gildan Activewear

$35.38

0.095 (0.27%)

BDN

Brandywine Realty

$14.68

0.13 (0.89%)

EXPO

Exponent

$70.82

1.34 (1.93%)

WDFC

WD-40

$182.75

2.41 (1.34%)

VICR

Vicor Corporation

$32.78

1.16 (3.67%)

OZK

Bank OZK

$28.32

0.03 (0.11%)

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 22

    Nov

MRTN Marten Transport
$21.52

0.31 (1.46%)

09/10/19
KEYB
09/10/19
UPGRADE
Target $25
KEYB
Overweight
Heartland Express upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Todd Fowler last night upgraded both Heartland Express (HTLD) and Marten Transport (MRTN) while reiterating Overweight ratings on Knight-Swift Transportation (KNX) and Werner (WERN). The analyst has increased conviction in stabilizing truckload dynamics on more seasonal trends and reduced incremental supply. His channel checks indicate lower demand and available capacity Q3-to-date, which he notes is largely in line with expectations. However, pricing outlooks have stabilized, Fowler tells investors in a research note. He has a $25 price target on Heartland Express.
09/10/19
KEYB
09/10/19
UPGRADE
Target $25
KEYB
Overweight
Marten Transport upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Todd Fowler last night upgraded both Heartland Express (HTLD) and Marten Transport (MRTN) while reiterating Overweight ratings on Knight-Swift Transportation (KNX) and Werner (WERN). The analyst has increased conviction in stabilizing truckload dynamics on more seasonal trends and reduced incremental supply. His channel checks indicate lower demand and available capacity Q3-to-date, which he notes is largely in line with expectations. However, pricing outlooks have stabilized, Fowler tells investors in a research note. He has a $25 price target on Marten Transport.
09/10/19
09/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. BHP Group (BHP) upgraded to Buy from Neutral at Goldman Sachs. 2. Marten Transport (MRTN) and Heartland Express (HTLD) upgraded to Overweight from Sector Weight at KeyBanc. 3. MercadoLibre (MELI) upgraded to Buy from Neutral at BTIG with analyst Marvin Fong saying the pullback in shares post-Argentina is overdone. 4. Schlumberger (SLB) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Connor Lynagh saying that while the stock struggled over the past several years, its relative outlook is improving. 5. Boston Properties (BXP) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Vikram Malhotra saying valuations are more reasonable today in the New York City office real estate investment trust space following this year's underperformance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/19
KEYB
09/09/19
UPGRADE
KEYB
Overweight
Marten Transport upgraded to Overweight from Sector Weight at KeyBanc
ISRG Intuitive Surgical
$529.22

-1.25 (-0.24%)

09/13/19
REDB
09/13/19
INITIATION
REDB
Buy
Intuitive Surgical initiated with a Buy at Redburn
09/25/19
PIPR
09/25/19
NO CHANGE
Target $633
PIPR
Overweight
Piper says Intuitive Surgical overhang over after Medtronic unveils Hugo
Medtronic (MDT) yesterday afternoon showcased its long-awaited multi-port surgical robot Hugo, which will compete with Intuitive Surgical's (ISRG) da Vinci, Piper Jaffray analyst Matt O'Brien tells investors in a research note. As expected, Medtronic's robot is a fully modular system with an open console design and 3D vision, says the analyst. He believes Hugo should garner interest from hospitals considering its value proposition. However, Medtronic's system is at least two years out from the U.S., and the company will not be giving the system away for free like some feared, explains O'Brien. Competition has been an overhang for Intuitive for the last several months, says O'Brien, who left yesterday "feeling A LOT better about Intuitive's competitive positioning and long term growth potential." He believes Intuitive Surgical's overhang is over and that the company is likely to remain the market leader. The analyst keeps an Overweight rating on the shares with a $633 price target. O'Brien also has an Overweight rating on Medtronic with a $120 price target.
07/19/19
MSCO
07/19/19
NO CHANGE
Target $620
MSCO
Overweight
Consensus view of Intuitive's placements looks conservative, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Intuitive Surgical's System average selling prices recovered in Q2 and its procedures came in above consensus, stating that he thinks the report should put the "mix debate to bed." Guidance implies stability into the back half of the year and "does not appear aggressive," said Lewis, who also thinks the consensus view on system placements looks conservative in the second half. He keeps an Overweight rating and $620 price target on Intuitive Surgical shares.
09/25/19
GUGG
09/25/19
NO CHANGE
GUGG
Neutral
Medtronic financial projections for Hugo robot 'underwhelming,' says Guggenheim
After attending Medtronic's (MDT) "much-anticipated" robotic-assisted surgery event, where the company gave a first look at the Hugo RAS system, Guggenheim analyst Chris Pasquale noted that the company gave an update on regulatory timelines and initial revenue targets, though information on pricing and clinical comparability to Intuitive Surgical's (ISRG) da Vinci system were "notably absent." He was impressed by certain design elements, though he thinks management's financial projections for Hugo were "somewhat underwhelming," said Pasquale, who keeps a Neutral rating on Medtronic shares.
ETFC E-Trade
$39.04

0.02 (0.05%)

10/09/19
DBAB
10/09/19
NO CHANGE
DBAB
Hold
Deutsche sees 'major' M&A as potential path for E-Trade, Ameritrade
Charles Schwab's (SCHW) move to cut trade commissions to zero is likely to spur business model changes at TD Ameritrade (AMTD) and E-Trade Financial (ETFC), Deutsche Bank analyst Brian Bedell tells investors in a research note. Instead of managing "persistent" revenue declines, management teams should seek to leverage their strong operating platforms and loyal customer base into a more diversified retail financial service offering that includes online banking, digital wealth management and investment advisory, argues the analyst. This may require "major" M&A for E-Trade and Ameritrade, while Schwab can likely augment its wider range of offerings organically or via smaller bolt on deals, says Bedell. He still views Ameritrade as the "most efficient acquirer" of E-Trade, but finds it no longer clear that the combination "would create a broad enough financial services offering for the new revenue paradigm." One alternative idea could be an E-Trade combination with a digital banking and wealth management platform, says the analyst, who analyzed a potential merger with Goldman Sachs (GS). Bedell also wonders if Ameritrade will eventually explore strategic alternatives or if 43% owner TD Bank (TD) will eventually seek to acquire a much larger controlling stake in the company.
10/07/19
10/07/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Match Group (MTCH) upgraded to Buy from Neutral at Nomura Instinet and to Buy from Hold at Deutsche Bank. 2. Uber (UBER) upgraded to Buy from Neutral at Citi with analyst Itay Michaeli saying the company's upcoming Q3 results should bring an acceleration in revenue growth and swing investment sentiment more favorably. 3. Arconic (ARNC) upgraded to Overweight from Neutral at JPMorgan with analyst Seth Seifman saying he sees a "compelling" risk/reward profile following the stock's 8% decline in the past two weeks. 4. JetBlue (JBLU) upgraded to Buy from Neutral at Buckingham with analyst Daniel McKenzie saying competitive capacity looks manageable at this point, but notes that his upgrade is likely "early," given IT initiatives that don't become material to revenue until the first quarter of 2020. 5. E-Trade (ETFC) and Moody's (MCO) upgraded to Buy from Neutral at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/14/19
KBWI
10/14/19
NO CHANGE
KBWI
Hard for Goldman, Morgan Stanley to justify E-Trade deal, says Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl looked into whether an acquisition of E-Trade (ETFC) would make sense for Goldman Sachs (GS) or Morgan Stanley (MS) after the electronic brokers reduced their commission rates. The analyst says he could make the strategic rationale for why a broker would buy an e-broker, namely cost savings and customer base expansion. However, ultimately a deal has to make sense financially as well, and it would be hard for Morgan or Goldman to justify on this basis, Kleinhanzl tells investors in a research note. In addition, with both brokers trading near tangible book value, shareholders would prefer buybacks versus an acquisition as a better use of shareholder capital at this point in the cycle, adds the analyst. As such a result, Kleinhanzl sees a deal for E-Trade as unlikely given the financial and capital impacts. He would be surprised if either broker aggressively pursued E-Trade as an acquisition.
10/09/19
JEFF
10/09/19
NO CHANGE
Target $43
JEFF
Buy
Jefferies says Schwab best positioned discount broker after commission cuts
Jefferies analyst Daniel Fannon said following last week's commission cut announcements that he views Charles Schwab (SCHW) as the best positioned discount broker to capitalize on trends in the industry toward fee-based advice and advisors going independent. Interest rates will "push around near-term profitability," but he believes Schwab's net new asset growth is poised to remain industry-leading, Fannon said. Among publicly traded companies in the space, Fannon still views E-Trade (ETFC) as the most likely M&A candidate, he added. Given the recent commission cuts, he lowered his price target on Schwab shares to $43 from $49, lowered his price target on E-Trade to $44 from $54 and cut his price target on TD Ameritrade (AMTD) to $36 from $55. Fannon has Buy ratings on the first two stocks mentioned and a Hold rating on TD Ameritrade.
WAL Western Alliance
$46.24

0.53 (1.16%)

04/24/19
WELS
04/24/19
NO CHANGE
Target $58
WELS
Outperform
Western Alliance price target raised to $58 from $53 at Wells Fargo
Wells Fargo analyst Timur Braziler raised his price target for Western Alliance to $58 from $53 after the company posted "the strongest quarter" of anyone in his coverage group, highlighted by excellent balance sheet trends, 20%-plus annualized tangible book value, and 20%-plus return on tangible common equity. The analyst reiterates an Outperform rating on the shares as he does not see material near-term risk threatening his 20%-plus annual growth estimates through 2020.
10/23/18
RHCO
10/23/18
NO CHANGE
Target $63
RHCO
Buy
Western Alliance price target lowered to $63 from $70 at SunTrust
SunTrust analyst Michael Young lowered his price target on Western Alliance to $63 to reflect the contraction in industry multiples but also keeps his Buy rating after the bank's Q3 results. The analyst notes that Western Alliance posted better net interest income growth than its peers thanks to a lower loan to deposit ratio and expects its net interest margins to remain supported.
01/15/19
SBSH
01/15/19
UPGRADE
Target $53
SBSH
Buy
Western Alliance upgraded to Buy from Neutral at Citi
Citi analyst Arren Cyganovich upgraded Western Alliance Bancorp to Buy while lowering his price target for the shares to $53 from $56.
08/23/19
WEDB
08/23/19
NO CHANGE
Target $55
WEDB
Outperform
Western Alliance added to Best Ideas List at Wedbush
Wedbush analyst David Chiaverini added Western Alliance to the firm's Best Ideas List, citing the company's above-average loan and deposit growth, de-risking of its balance sheet, strong tangible book value growth and "attractive" valuation. Chiaverini tells investors in a research note that he expects the stock's valuation multiple to expand relative to peers, and believes NII will continue to grow in the the low double digits this year and high single digits in 2020 driven by above-average growth in loans and deposits.
TEAM Atlassian
$122.43

-1.91 (-1.54%)

10/11/19
OPCO
10/11/19
NO CHANGE
OPCO
Oppenheimer lowers price targets for MongoDB, Twilio, New Relic ahead of reports
Oppenheimer analyst Ittai Kidron said he expects solid results from the Analytics, Collaboration, and Infrastructure software group, though upside may be more constrained given several vendors face tougher year-over year comparisons and it seems investors have become more sensitive to high valuations. While he said MongoDB (MDB), Twilio (TWLO), Smartsheet (SMAR) and Elastic (ESTC) remain top picks, he sees lower near-term upside given tough comps in the second half and sees them as better positioned to deliver bigger upside in calendar 2020, Kidron tells investors in his group preview. Ahead of results from the group, Kidron lowered his price target for MongoDB to $155 from $180, for Twilio to $145 from $160 and for New Relic (NEWR) to $80 from $85. He also noted that he is bullish on Alteryx (AYX), Atlassian (TEAM) and VMware (VMW).
10/11/19
OPCO
10/11/19
NO CHANGE
Target $140
OPCO
Outperform
Okta announced innovative products and partnerships, says Oppenheimer
Okta (OKTA) remains "laser focused" on identity centric security, which is based on Zero Trust and a dissolving network perimeter, Oppenheimer analyst Shaul Eyal tells investors in a research note following the company's Showcase Event. The analyst continues to see a "sizeable market opportunity" for the company and keeps an Outperform rating on the shares with a $140 price target. Key takeaways from the event include the announcement of DynamicScale, a customer-identity-focused solution able to support peak loads during traffic bursts up to 500,000 authentications per minute, and SecurityInsights, a security detection and remediation technology designed to improve an organization's security posture, as well as partnerships with Atlassian (TEAM) and Proofpoint (PFPT), says Eyal.
10/02/19
RHCO
10/02/19
INITIATION
RHCO
Buy
Atlassian initiated with a Buy at SunTrust
SunTrust analyst Joel Fishbein initiated Atlassian with a Buy rating and $162 price target.
10/02/19
RHCO
10/02/19
INITIATION
RHCO
SunTrust initiates infrastructure and security sector
SunTrust analyst Joel Fishbein initiated fourteen stocks in the infrastructure and security sector. Regarding infrastructure, he said he believes "we are in the 3rd inning of a multi year (even multi-decade) opportunity" and projected on-demand penetration of 70% by 2028, adding that "spending on cloud software is projected to grow at ~3x the overall software market rate, resulting in a greater than $208B market opportunity through 2025." However, Fishbein cautioned to "stay selective" as while he is bullish on the underlying trends, "too many investors are chasing too few stories." For cybersecurity, Fishbein noted that it remains a top priority for the corporations, and cited the IDC stating that "worldwide spending on security-related hardware, software, and services is forecast to reach $133.7B in 2022 at a compound annual growth rate of 9.9%." He believes that emerging vendors with innovative technology are growing much faster, and sees a "shift in spending from legacy security providers to next generation technology providers and multi-product platforms." The analyst started eight names with Buy ratings -- Atlassian (TEAM), New Relic (NEWR), ServiceNow (NOW), Splunk (SPLK), Palo Alto Networks (PANW), Rapid7 (RPD), SailPoint (SAIL), and Zscaler (ZS). The other six names Fishbein started with Hold ratings -- PagerDuty (PD), Check Point (CHKP), FireEye (FEYE), Proofpoint (PFPT), Qualys (QLYS), and Tenable Holdings (TENB).
PRTK Paratek Pharmaceuticals
$3.46

0.05 (1.47%)

03/18/19
ADAM
03/18/19
NO CHANGE
ADAM
Paratek CFO departure not concerning, says Canaccord
Canaccord analyst Dewey Steadman maintained a Buy rating and $25 price target on Paratek Pharmaceuticals, saying he is not concerned by the departure of CFO Doug Pagan as he left the company "in good shape." Steadman continues to see an "attractive entry point for what could be one of the most compelling true antibacterial product launches in the past several years" in Nuzyra.
01/16/19
ADAM
01/16/19
NO CHANGE
Target $25
ADAM
Buy
Paratek Pharmaceuticals price target raised to $25 from $14 at Canaccord
Canaccord analyst Dewy Steadman raised his price target on Paratek Pharmaceuticals to $25 from $14 following meetings with management. The analyst came away encouraged that the story sets up well with reasonable expectations for 2019. He also said the company's stretch goal of $500M in Nuzyra revenue by 2024 is positively surprising and potentially achievable, but remains out of his estimates for now. Steadman reiterated his Buy rating on Paratek Pharmaceuticals shares.
03/12/19
ADAM
03/12/19
NO CHANGE
Target $25
ADAM
Buy
Canaccord continues to see attractive entry point for Paratek
Canaccord analyst Dewey Steadman maintained a Buy rating and $25 price target on Paratek Pharmaceuticals following the release of the company's 10-K. In a research note to investors, Steadman says he is "encouraged" by the company's initial marketing efforts for Nuzyra and sees initial revenue guidance of $10M-$13M as achievable. As Nuzyra gains market acceptance over the coming quarters, Steadman says he likes the Paratek story and continues to see an attractive entry point for what could be one of the most compelling true antibacterial product launches in the past several years;
05/09/19
WEDB
05/09/19
NO CHANGE
Target $12
WEDB
Outperform
Paratek Pharmaceuticals price target lowered to $12 from $17 at Wedbush
Wedbush analyst Robert Driscoll lowered his price target for Paratek Pharmaceuticals to $12 from $17 following quarterly results. The analyst sees a measured launch ahead for Nuzyra, with momentum continuing toward an "ultimately successful" commercial launch of a differentiated antibiotic. He reiterates an Outperform rating on the shares.
GIL Gildan Activewear
$35.38

0.095 (0.27%)

08/02/19
DESJ
08/02/19
UPGRADE
DESJ
Buy
Gildan Activewear upgraded to Buy from Hold at Desjardins
08/02/19
DESJ
08/02/19
UPGRADE
DESJ
Buy
Gildan Activewear upgraded to Buy from Hold at Desjardins
Desjardins analyst Keith Howlett graded Gildan Activewear to Buy from Hold and raised his price target for the shares to C$57 from C$48 following the company's Q2 results. Amid increasing trade tensions between the U.S. and China, Gildan will be "relatively well-positioned" as most of its production utilizes U.S. cotton yarn and is based in Central America, Howlett tells investors in a research note. Further, he believes the company's gross margin rate will begin to visibly improve in Q4 and further increase in 2020, potentially reaching the targeted 30% in 2021.
03/27/19
BMOC
03/27/19
NO CHANGE
Target $36
BMOC
Market Perform
Pressure on Gildan Activewear from Heritage charge to be brief, says BMO Capital
BMO Capital analyst Stephen MacLeod is keeping his Market Perform rating and $36 price target on Gildan Activewear, saying the stock may come under pressure after the company cut its Q1 guidance to reflect a trade receivable impairment from Heritage Sportswear. The analyst believes that the pressure would be short-lived however, noting that any "lost sales are likely to be absorbed by other distributors", resulting in minimal change to Gildan's FY19 sales. MacLeod continues to see a balanced risk-reward for the stock, adding that the Heritage loss "incrementally increases Gildan's customer concentration."
08/02/19
TDSI
08/02/19
UPGRADE
TDSI
Buy
Gildan Activewear upgraded to Buy from Hold at TD Securities
BDN Brandywine Realty
$14.68

0.13 (0.89%)

02/04/19
LEHM
02/04/19
NO CHANGE
LEHM
Barclays upgrades U.S. REITs sector to Positive from Neutral
Barclays analyst Ross Smotrich upgraded his sector rating on U.S. Real Estate Investment Trusts to Positive from Neutral. Late cycle concerns around slowing growth, rising interest rates and full asset values are overdone, Smotrich tells investors in a research note. The analyst believes that real estate fundamentals "have a good runway for continued strength, particularly compared to the slowing broader market." In Multifamily, the analyst upgraded the sub-sector to Positive, reiterates Overweight ratings on Essex Property Trust (ESS) and MAA (MAA), upgraded Camden Property Trust (CPT) to Overweight from Equal Weight for exposure to "18 hour cities" and downgraded Aimco (AIV) to Equal Weight from Overweight on slowing growth. In Office, Smotrich keeps a Neutral sub-sector rating "with a Positive tilt." His outlook for the sector is improving given "healthy underlying fundamentals and attractive valuations." He upgraded both SL Green Realty (SLG) and Brandywine Realty (BDN) to Overweight from Equal Weight, and Douglas Emmett (DEI) to Equal Weight from Underweight. The analyst maintain Overweight ratings on Alexandria Real Estate (ARE), Boston Properties (BXP) and Hudson Pacific (HPP). In Retail, the analyst tells investors to stay selective. He prefers larger companies with "better-quality assets, balance sheet flexibility, the ability to take share and grow earnings even as retailers evolve and rationalization store counts." Smotrich upgraded Regency Centers (REG) to Overweight from Equal Weight, reaffirmed Overweights on both Kimco Realty (KIM) and Simon Property (SPG), and downgraded Kite Realty Group (KRG) to Equal Weight from Overweight.
02/25/19
BOFA
02/25/19
DOWNGRADE
BOFA
Neutral
Brandywine Realty downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst James Feldman downgraded Brandywine Realty to Neutral and lowered its price target to $16.50 from $17 to reflect lower earnings visibility.
06/11/19
BOFA
06/11/19
DOWNGRADE
Target $15.5
BOFA
Underperform
Brandywine Realty downgraded to Underperform from Neutral at BofA/Merrill
BofA Merrill Lynch analyst James Feldman downgraded Brandywine Realty to Underperform from Neutral after lowering his FFO estimates following his talks with management at the Nareit meeting. Feldman, who noted that his 2020 estimate is below consensus and that he forecasts below average earnings growth through 2021, cut his price target for Brandywine shares to $15.50 from $16.50.
07/08/19
ARGS
07/08/19
UPGRADE
Target $17
ARGS
Buy
Brandywine Realty upgraded to Buy from Hold at Argus
Argus analyst Jacob Kilstein upgraded Brandywine Realty to Buy from Hold with a price target of $17, saying the company's FFO has topped expectations for the past four quarters as the REIT appears to be "thriving at the tail end of its repositioning and asset sales." The analyst also believes that the expected decline in interest rates should benefit the relatively higher-yielding REITs like Brandywine and sees its valuation of 10.1-times his expected FY19 FFO as attractive relative to the 14.9-times multiple average for other office REITs.
EXPO Exponent
$70.82

1.34 (1.93%)

08/28/19
DADA
08/28/19
INITIATION
Target $65
DADA
Neutral
Exponent initiated with a Neutral at DA Davidson
DA Davidson started Exponent with a Neutral rating and $65 price target.
08/28/19
DADA
08/28/19
INITIATION
Target $65
DADA
Neutral
Exponent initiated with a Neutral at DA Davidson
DA Davidson analyst Alexis Huseby initiated Exponent with a Neutral rating and a price target of $65. The analyst cites the company's "steady" track record of growth with 6% CAGR in the 2009-2018 period and also notes its breadth with over 2K clients covering 18 areas of expertise. However, Huseby points to Exponent's 28-times forward EBITDA valuation as well as its tough comps expected in FY19 and believes that it will be "difficult to generate attractive returns over the next 12 months."
08/29/19
08/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) initiated with a Buy at Loop Capital. 2. Exponent (EXPO) initiated with a Neutral at DA Davidson. 3. Dova Pharmaceuticals (DOVA) initiated with an Outperform at Oppenheimer. 4. Cree (CREE) initiated with an Underperform at Exane BNP Paribas. 5. MarketAxess (MKTX) initiated with a Hold at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/19
RHCO
09/20/19
NO CHANGE
Target $81
RHCO
Buy
Exponent price target raised to $81 from $70 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on Exponent to $81 and kept his Buy rating, saying the company is in a "stout competitive position" with expectation of a mix shift toward "lucrative large proactive work". The analyst adds that the longer-term societal focus on safety, health, and sustainability amid growing technological complexity are long-term demand drivers for Exponent. Sommer further notes that the company has a broad competitive moat and sees risk management in the utility industry as a multi-year catalyst for Exponent.
WDFC WD-40
$182.75

2.41 (1.34%)

10/15/19
DADA
10/15/19
NO CHANGE
Target $209
DADA
Buy
WD-40 sets up favorably for FY20, says DA Davidson
DA Davidson analyst Linda Bolton Weiser is keeping her Buy rating and $209 price target on WD-40 ahead of its Q4 earnings release this week. The analyst notes that while she is keeping her below-guidance revenue forecast based on the continued weakness in the British Pound, she expects the company's petroleum-based input cost comparison to improve for the third straight quarter, yielding the highest gross margin rate since Q1 of 2017. Weiser adds that the consensus for WD-40 earnings in FY20 looks "reasonable" based on the "favorable commodity cost comp" and the expected product innovation expected in the second half of FY20.
12/07/18
DADA
12/07/18
INITIATION
Target $209
DADA
Buy
WD-40 initiated with a Buy at DA Davidson
DA Davidson analyst Linda Bolton Weiser initiated WD-40 with a Buy rating and a price target of $209. The analyst cites the company's targeting of sales reaching $700M in FY25, which implies an annualized growth of about 8% and represents a step-up from its 2%-5% historical rate. Weiser also notes WD-40's EBITDA margin forecast of 25% vs. 22% in FY18 along with its FY19 guidance of $4.51-$4.58 being achievable if oil prices can stay below $60 a barrel for another two months. Lastly, the analyst cites the company's expectations of a next "margin-accretive major innovation" announcement in March of 2019.
04/08/19
DADA
04/08/19
NO CHANGE
Target $209
DADA
Buy
WD-40 approaching margin inflection point, says DA Davidson
DA Davidson analyst Linda Bolton Weiser kept her Buy rating and $209 price target on WD-40 ahead of its Q2 earnings tomorrow, saying the company is likely to beat expectations on revenue and post an in-line earnings of $1.12 per share. The analyst notes that while oil price moved from $52 to $63 per barrel since the company's last update in January, she expects WD-40 to maintain its guidance because the management has previously assumed $70-$75 per barrel oil price. Weiser adds that she still sees petroleum-based input costs to be down in Q3 and for the company to post its first gross margin expansion since Q2 of 2017.
VICR Vicor Corporation
$32.78

1.16 (3.67%)

08/12/19
08/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mirum Pharmaceuticals (MIRM) initiated with an Outperform at Raymond James and Evercore ISI, as well as a Buy at Roth Capital, Citi, and Guggenheim. 2. Intra-Cellular (ITCI) initiated with a Buy at Jefferies. 3. Vicor Corporation (VICR) initiated with a Buy at Craig-Hallum. 4. AssetMark Financial (AMK) initiated with an Outperform at Raymond James, a Buy at Goldman Sachs, a Market Perform at William Blair, and a Neutral at JPMorgan. 5. DTE Energy (DTE) initiated with a Neutral at Mizuho. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/12/19
CHLM
08/12/19
INITIATION
Target $43
CHLM
Buy
Vicor Corporation initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Richard Shannon started coverage of Vicor Corporation with a Buy rating and a $43 price target. The analyst believes sustainable 20%-plus year over year topline growth is possible starting in the second half of 2019 which should drive material EPS growth. Furthermore, Shannon sees potential for the stock to reach $150.
04/10/19
NORL
04/10/19
INITIATION
Target $36
NORL
Outperform
Vicor Corporation initiated with an Outperform at Northland
Northland analyst Gus Richards initiated Vicor Corporation with an Outperform and $36 price target saying it is a provider of energy efficient power delivery technology with marquee customers including Google, nVidia, and Cray. Vicor's proprietary technology is used to deliver power in the most challenging applications and will benefit from increased use in hyperscale datacenters and AI applications, the analyst wrote in a note to investors.
10/08/19
NEED
10/08/19
INITIATION
Target $42
NEED
Buy
Vicor Corporation initiated with a Buy at Needham
Needham analyst N. Quinn Bolton initiated Vicor Corporation with a Buy rating and a price target of $42 while adding the stock to his firm's Conviction list. The analyst contends that the company is "uniquely positioned" to benefit from greater power efficiency demand, higher requirements of advanced processors, and the transition to 48V architectures in the data center thanks to its "revolutionary" Factorized Power Architecture. Bolton adds that Vicor has emerged as the "supplier of choice" in 48V and AI accelerator power management solutions while developing strong relationships with major CPU, GPU, and AI accelerator companies.
OZK Bank OZK
$28.32

0.03 (0.11%)

01/22/19
RHCO
01/22/19
NO CHANGE
Target $35
RHCO
Hold
Bank OZK price target raised to $35 from $25 at SunTrust
SunTrust analyst Jennifer Demba raised her price target on Bank OZK to $35 after its Q4 earnings and preliminary FY19 guidance. The analyst cites the company's net interest margin expansion given the easing in deposit pricing, along with the management's greater focus on deposit gathering and pricing analytics. Demba also notes the subsiding asset quality fears for the bank, with commercial real estate loan project sales velocity and pricing holding up and net charge offs coming in "more normal" in the quarter. The analyst keeps her Hold rating on the shares after their 40% run-up year to date.
01/22/19
BMUR
01/22/19
NO CHANGE
Target $38
BMUR
Buy
Bank OZK discount provides upside opportunity, says Brean Capital
Brean Capital analyst Blair Brantley noted Bank OZK reported solid Q4 results highlighted by NIM expansion, favorable net loan growth, fee income expansion, and more typical credit related results. He raised his estimates but said it remains a "show-me" story for the next few quarters. Brantley believes upside exists as additional quarters like Q4 are achieved. Brantley reiterated his Buy rating and $38 price target on Bank OZK shares.
01/10/19
LEHM
01/10/19
NO CHANGE
LEHM
Barclays upgrades Mid-Cap Banks industry to Positive from Neutral
Barclays analyst Matthew Keating upgraded his view on the U.S. Mid-Cap Banks industry to Positive from Neutral. There seems to be a lot less enthusiasm for the banks this year, Keating tells investors in a research note. The focus this year is on rising trade tensions, slowing global growth, and chance of a recession, says the analyst. However, he believes the slide in bank stock sentiment creates opportunities for investors "willing to withstand some volatility in the near term." Along with the sector, Keating upgraded Synovus Financial (SNV) and Texas Capital (TCBI) to Overweight from Equal Weight and Bank OZK (OZK) and People's United Financial (PBCT) to Equal Weight from Underweight. Based on his relative ratings system, he downgraded Prosperity Bancshares (PB) to Equal Weight from Overweight and New York Community Bancorp (NYCB) to Underweight from Equal Weight.
01/22/19
LEHM
01/22/19
NO CHANGE
Target $36
LEHM
Overweight
Bank OZK price target raised to $36 from $28 at Barclays
In a post-earnings research note titled "What a Difference a Year Can Make," Barclays analyst Matthew Keating raised his price target for Bank OZK to $36 from $28 and keeps an Overweight rating on the shares. OZK's preliminary 2019 outlook calls for low-to-mid-teens non-purchased loan growth, moderation in its cost of interest bearing deposits, and continued "excellent" asset-quality trends, Keating writes. He thinks the company drives high-single-digit loan and earnings growth this year.

TODAY'S FREE FLY STORIES

11:25
12/08/19
12/08
11:25
12/08/19
11:25
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.